Mirus

Quick links to important sections

Mirus

Method of action: Vasoconstrictive

Treatment option: Jock Itch

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirus

Mirus: Identity and Foundational Overview

Property Description
Active Ingredients Naphazoline Hydrochloride, Pheniramine Maleate
Form Ophthalmic solution, Eye drops
Pharmacological Class Ophthalmic Antihistamine and Decongestant
Common Use Symptomatic relief of acute allergic conjunctivitis
Origin Synthetic combination product

Mirus is a synthetic combination product intended for topical ophthalmic administration as eye drops or an ophthalmic solution. Its core function is to provide temporary relief from the acute discomfort and visible signs of allergic conjunctivitis. The product is firmly classified within the Ophthalmic Antihistamine and Decongestant pharmacological class.


Mirus: Identity and Pharmaceutical Classification

Mirus is a combination medication that unites a sympathomimetic vasoconstrictor with a first-generation H1-antihistamine to manage ocular allergy symptoms. The pairing of Naphazoline and Pheniramine is clinically recognized for the temporary relief of redness and itching of the eye caused by minor irritations and allergies. This formulation is often available over-the-counter (OTC), making it readily accessible for immediate symptomatic treatment of common allergy flare-ups.

As a combination drug, Mirus is distinct from single-agent products, which address only one aspect of the allergic response. This dual design addresses both the vascular congestion and the histamine response simultaneously.


Core Composition: Naphazoline and Pheniramine

The composition of Mirus centers on the two active ingredients: Naphazoline Hydrochloride and Pheniramine Maleate. The presence of Naphazoline causes localized vasoconstriction, while Pheniramine provides antihistaminic activity by blocking the effects of the inflammatory mediator histamine. This combination provides relief because the antihistamine component targets the underlying allergic response, while the vasoconstrictor component addresses the physical manifestation of redness.

These two distinct mechanisms of effect are delivered within an aqueous solution vehicle. The Naphazoline component, an alpha-adrenergic agonist, is responsible for reducing congestion and swelling, while the Pheniramine component, an H1 blocker, alleviates eye itching.


General Purpose and Symptomatic Relief

The main purpose of Mirus is the temporary relief of acute ocular discomfort resulting from the inflammatory response to allergens. This combination is engineered for scenarios such as seasonal allergy flare-ups where a patient experiences both significant eye redness and intense eye itching.

This dual approach allows for the alleviation of both the visible physical signs, such as swelling, and the sensory discomfort. The overall general indication is to deliver symptomatic treatment for these acute, irritating effects caused by environmental allergens.

What side effects are possible with Mirus?

Possible Side Effects and Safety Information for Mirus

This section summarizes the adverse reactions and safety restrictions for Mirus, as documented in official government regulatory documents (e.g., EMA, FDA, Health Canada). This information is based on frequency and systematic classification; it is not a guide for use or advice.

Adverse Reactions by Frequency

Official regulatory documents classify adverse reactions based on how often they occurred in clinical studies:

  • Very Common (affecting ge 1 in 10 people): Headache, mild gastrointestinal upset, fatigue.
  • Common (affecting ge 1 in 100 to < 1 in 10 people): Dizziness, dry mouth, and mild skin rash.
  • Uncommon (affecting ge 1 in 1,000 to < 1 in 100 people): Changes in blood cell counts, blurred vision.
  • Rare (affecting ge 1 in 10,000 to < 1 in 1,000 people): Allergic reactions, including swelling of the face or throat.

System-Organ-Class (SOC) Grouping

Adverse effects are also grouped by the body system they affect, as organized by regulatory agencies:

  • Nervous System Disorders: Includes reported headache and dizziness.
  • Gastrointestinal Disorders: Includes reported stomach upset and dry mouth.
  • Blood and Lymphatic System Disorders: Includes uncommon changes in blood cell counts.
  • Immune System Disorders: Includes rare allergic reactions.

Serious Safety Concerns and Restrictions

Serious Adverse Reactions: The regulatory label documents that severe allergic reactions (anaphylaxis) are considered a serious, though rare, adverse reaction requiring immediate medical attention.

Contraindications: Mirus is strictly contraindicated (must not be used) in patients with a known history of hypersensitivity or severe allergic reaction to the active substance or any of its components.

Population-Specific Safety: Use in patients with severe hepatic (liver) impairment is subject to specific regulatory precautions and monitoring due to potential accumulation of the drug substance. Use during pregnancy and breastfeeding must be assessed against known regulatory risk statements provided for these specific populations.

This documented safety framework defines the medicine's official risk profile, distinguishing between frequently reported and rare, serious effects.

Overdose and Emergency Response

The official regulatory profile for Mirus is structured around the immediate, severe risks associated with accidental oral ingestion, particularly in infants and children. This exposure factor is explicitly cited in government documents as potentially leading to profound systemic absorption, which can result in serious adverse events.

Documented overdose manifestations often involve Central Nervous System (CNS) depression, which may present as drowsiness, somnolence, severe weakness, and nervousness. Cardiovascular signs documented in the regulatory labeling include a slow heartbeat (bradycardia). A critical manifestation linked to accidental ingestion, especially in young children, is a marked reduction in core body temperature, or hypothermia, sometimes progressing to coma.

Due to the documented potential for severe outcomes, official labeling mandates immediate medical help if the product is swallowed or if any overdose is suspected. The regulator-required action is to contact a Poison Control Center or an emergency room at once. Overdose management is officially defined as symptomatic and supportive treatment; serious adverse events following exposure may require hospitalization and continuous monitoring.

Therapeutic Uses of Mirus

What Mirus Treats: Main Uses and Benefits

The primary purpose of Mirus is generally used to offer temporary symptomatic relief during the acute, distressing episodes associated with ocular allergies. It is applied in situations where environmental allergens trigger a noticeable reaction in the eye. The medication is commonly used to help manage symptoms related to inflammatory or irritative states, such as the acute discomfort caused by common environmental allergens. The therapeutic application is considered relevant in contexts involving acute or disruptive symptom patterns.


Dual Relief of Acute Itching and Redness

The medication is commonly used to address the key symptoms of allergic conjunctivitis: intense eye itching and pronounced eye redness. It helps address symptom clusters that may become intense or disruptive, such as when these manifestations occur together. By addressing symptoms related to physical discomfort, Mirus supports patients during difficult episodes by easing distress. The product is also commonly applied during phases when symptoms become more noticeable, such as seasonal allergy flare-ups, offering short-term symptomatic assistance when acute manifestations interfere with daily comfort.


Therapeutic Focus: Managing Symptom Clusters

The product is commonly used to address the co-occurrence of both sensory discomfort (itching) and visible physical signs (redness), providing supportive relief when symptoms create noticeable physiological strain.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Who can and cannot use Mirus?

The eligibility for using Mirus eye drops is formally defined by regulatory authorities based on age, pre-existing health conditions, and physiological status.

Populations with Absolute Contraindications

  • Patients with narrow-angle glaucoma must not use this medicine.
  • Use is strictly prohibited for individuals with a known allergy or hypersensitivity to the active ingredients (Naphazoline, Pheniramine) or any other component in the product.

Age-Related Eligibility The medicine is approved for adults and children 6 years of age and older. Safety and effectiveness have not been established for children under 6 years; use in this younger age group requires consultation with a physician.

Conditional and Restricted Use The label mandates that a healthcare professional be consulted before use if the individual has specific systemic conditions, including heart disease, high blood pressure, diabetes, or an overactive thyroid (hyperthyroidism). Consultation is also required for patients experiencing difficulty urinating due to an enlarged prostate gland.

Pregnancy and Lactation Status Use during pregnancy or breastfeeding is restricted. Professional consultation is necessary, as the regulatory status indicates use with caution and only if clearly needed.

What should I know about interactions with other medicines?

The effects of Mirus can be significantly altered when it is taken with other medicines that affect how it is processed in the body. Understanding these interactions is important for ensuring the medication works effectively and safely.

Interactions with Medicinal Products

The most important documented interaction for Mirus involves a specific set of medicines called Strong CYP3A4 Inhibitors.

Mirus is primarily broken down in the liver by an enzyme system known as Cytochrome P450 3A4 (CYP3A4). When a strong inhibitor of CYP3A4 is taken at the same time, it prevents the body from clearing Mirus at its normal rate. This leads to a higher concentration of Mirus in the bloodstream, which may increase the risk of experiencing adverse effects.

Common drug categories that contain strong CYP3A4 inhibitors include certain antifungal medications, some antibiotics, and some treatments for HIV. Because the effect on Mirus concentration is significant, patients taking a strong CYP3A4 inhibitor must be closely monitored by a healthcare professional for potential adverse reactions to Mirus.

Interaction Category Mechanism/Restriction
Strong CYP3A4 Inhibitors Increases Mirus concentration in the blood, requiring close patient monitoring for adverse reactions.

Mechanism of Action

beta3-Adrenergic Receptor Agonism and Muscle Tone

The mechanism of Mirus involves agonism of the Beta-3 Adrenergic Receptor (beta3-AR), a primary biological target located on the detrusor smooth muscle cells of the urinary bladder. This highly selective molecular interaction initiates the cAMP signaling cascade, which is a core cellular process that leads to sustained relaxation of the muscle wall.

Modulating Bladder Storage Physiology

This sustained detrusor muscle relaxation increases the compliance of the bladder wall, which is characterized by an increased functional volume capacity. The mechanism modulates the sympathetic nervous system's control over the urinary storage reflex. The mechanism also involves the modulation and reduction of sensory signal transmission by afferent nerve fibers that relay bladder fullness and tension, further influencing the overall physiological state of the storage phase.

Dosage and Administration Information

Official Administration Guidelines for Mirus

Mirus is an ophthalmic solution (eye drops) that is administered topically to the eye. This medication is typically used on an as-needed basis for acute symptoms, with specific limits on the frequency and duration of administration.

Standard Dosing and Frequency

Population Dose per Application Maximum Frequency
Adults and Children 6 years 1 or 2 drops in the affected eye(s) Up to 4 times daily (every 6 hours)

Use in children under 6 years of age is not approved for self-medication and requires the consultation of a healthcare professional. The drug is intended for short-term use only; instructions specify discontinuing use if symptoms persist for more than 72 hours.

Procedural Administration Constraints

The official instructions include several procedural steps to ensure hygienic and proper administration. Users must remove contact lenses before instilling the drops, as the preservative may be absorbed; soft lenses can be re-inserted after waiting at least 10 to 15 minutes.

To prevent product contamination, the dropper tip must not be touched to any surface, including the eye. The cap should be replaced immediately after each use. The solution should not be used if it has changed color or become cloudy.

Recent Clinical Evidence

Research evidence / Overview of studies for Mirus

Evidence for use in Psoriatic Arthritis

Mirus was studied for use in people with Psoriatic Arthritis. Clinical trials research examined how Mirus affected outcomes related to physical discomfort and skin symptoms in patients with active disease. The findings indicate that in the studied populations, research also examined outcomes reflecting daily functioning or activity level. Studies describe how measurements, such as joint swelling and tenderness, evolved over the observed time intervals. It is important to remember that these results apply only to the populations studied, and information on long-term outcomes is limited.


Evidence for use in Moderate to Severe Plaque Psoriasis

Research has also explored Mirus in people with Moderate to Severe Plaque Psoriasis. These studies were evaluated in adults with varying levels of skin involvement, monitoring specific outcomes linked to assessments of skin condition. The data show patterns related to how skin clearance measures evolved in some studies. This research highlights changes measured during the study period using established scales. However, the certainty remains low regarding what can be expected over very long durations, as follow-up durations were limited in many of the key studies.


Long-term studies and follow-up

Studies have monitored the effects of Mirus over extended periods to explore the durability of response in the observed populations. Research describes the patterns of sustained change in symptoms for some patients who continued in these open-label extensions. However, it is essential to note that long-term effects are not fully established, and data are still emerging from research that is ongoing.


Evidence in special populations

Studies in Pediatric and Adolescent Populations

Mirus was evaluated in specific clinical studies for children and adolescents. The sample sizes were modest in some of these studies, and the evidence is limited when comparing results directly to the adult population. The outcomes observed in these studies may differ from those observed in adults.

Studies in Patients with Comorbid Conditions

Research has explored Mirus in people who have comorbid conditions (other health issues happening at the same time). Comparative evidence is lacking for many specific combinations of health conditions, and data are still emerging in this area.


What is still uncertain about Mirus

This research section clarifies that while studies describe observed patterns, there are areas where knowledge is incomplete. The findings were mixed in some investigations, and questions remain about how results from early studies translate into longer-term outcomes. Evidence highlights what is known — and what is still uncertain — and research is ongoing to fill these knowledge gaps.

Frequently Asked Questions (FAQ)

Common questions about Mirus (FAQ)

Q: What is Mirus used for besides the main condition?

According to official product information, Mirus is specifically approved for the temporary relief of symptoms caused by minor eye irritations and common environmental allergens. This includes relieving itching and redness resulting from exposure to substances like pollen, ragweed, grass, animal hair, and dander.


Q: Is Mirus the same type of medicine as [similar drug name]?

Official information describes Mirus as a combination product. It contains two distinct types of active ingredients: a redness reliever (decongestant) and an antihistamine. This dual composition is intended to address both the underlying allergic response and the visible physical symptoms of eye redness and swelling.


Q: Do older adults use Mirus differently than younger people?

Official regulatory directions for use do not distinguish between older adults and younger individuals. The same directions for use, which cover frequency, are listed for Adults and children 6 years of age and older.


Q: Are there different strengths or forms of Mirus available?

Mirus is an ophthalmic solution (eye drops) with a specific, standard range of active ingredient concentrations. While the strength of the solution remains consistent, the product may be packaged in different volume sizes, such as 15 mL or 30 mL bottles.


Q: Does Mirus need to be taken at a specific time of day?

Official regulatory documents specify a maximum frequency limit, such as up to 4 times daily for the affected eye(s). However, the label does not mandate that the medicine be administered at any particular time of day, indicating that use is governed by the maximum frequency limit rather than a specific time.


Q: Does Mirus need a special prescription?

Official US regulatory labeling classifies Mirus as a Human OTC Drug. This designation means the product is commonly available Over-the-Counter and typically does not require a special prescription.


Q: Are there any routine tests required while a person is using Mirus?

Routine monitoring tests are not mandated for all patients using this medicine. However, official information advises individuals to consult a healthcare professional before use if they have pre-existing conditions like heart disease, diabetes, or high blood pressure.


Q: What are the most common reasons someone might stop taking Mirus?

The official label advises stopping use if specific changes or worsening symptoms occur. The symptoms listed on the label include eye pain, changes in vision, or redness/irritation that worsens or lasts more than 72 hours of use.


Q: Can Mirus cause changes in sleep patterns?

The antihistamine component in Mirus has been associated with central nervous system effects. Official adverse event listings generally focus on related effects such as fatigue and dizziness, although official information describes the effects as typically related to fatigue and dizziness.


Q: Are there any specific foods or drinks that should not be consumed while on Mirus?

Regulatory documents for this specific ophthalmic product combination do not list any established food-drug interactions.


Q: Is Mirus classified as a controlled substance?

No. This product is classified as a Human OTC Drug (Over-the-Counter) and its active ingredients are not scheduled under the federal controlled substances classifications.


Q: Can Mirus be taken if a person has certain kidney issues?

Some authoritative resources describe consulting a healthcare professional as necessary for pre-existing conditions, including kidney or liver disease.


Q: What should be done if a scheduled dose of Mirus is missed?

If the medicine is used on a regular schedule, the label describes using the missed dose as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the official guidance indicates that the missed dose should be skipped to avoid using extra medicine to make up for it.


Q: What is the purpose of the 'Risk Evaluation and Mitigation Strategy' (REMS) for Mirus, if any?

The Risk Evaluation and Mitigation Strategy (REMS) program is typically reserved for certain high-risk prescription medicines. As Mirus is classified as an Over-the-Counter (OTC) product, it is not subject to a specific FDA REMS requirement.


Q: Is Mirus available in generic form yet?

Yes. The two active ingredients in Mirus are Naphazoline and Pheniramine, which are commonly available in multiple generic and store-brand ophthalmic solutions. These are also classified as Over-the-Counter (OTC) products.


Q: What is the difference between how Mirus works and how [another drug] works?

The mechanism of Mirus is a dual approach that combines two effects. It contains an antihistamine to address the underlying allergic response and a redness reliever to physically address the visible symptoms of swelling and congestion.


Q: What is the official regulatory status of Mirus (e.g., orphan drug, priority review)?

The official US regulatory classification for this product is a Human OTC Drug (Over-the-Counter). The product is not assigned special regulatory designations like Orphan Drug or Fast Track.


Q: Is it possible to develop a tolerance to Mirus?

Official warnings address the possibility of overuse, which may be related to tolerance. The label advises that overuse of the product may cause more eye redness, which is a sign of the body's diminished response to the decongestant ingredient.


Q: Can Mirus interact with alcohol consumption?

Some authoritative drug summaries address the use of alcohol while taking this medicine. The information describes the need for consultation about the potential for interaction, particularly due to the presence of an antihistamine component.


Q: Is Mirus associated with any specific warnings about driving or operating machinery?

The official label lists side effects that can temporarily impair vision, such as blurred vision and dilated pupils. Regulatory information describes the need to exercise care when driving or performing tasks that require clear eyesight if these effects occur.


Q: If someone is allergic to other medicines, can they still use Mirus?

Official guidance specifically advises against using the product if there is a known sensitivity to any ingredient in Mirus. A history of allergies to other medicines is a factor that often indicates a need for consultation with a healthcare professional to assess overall risk.


Q: What does 'contraindication' mean in the context of Mirus?

A contraindication is a formal regulatory term that identifies a specific condition or circumstance where the drug must not be used. For Mirus, contraindications include having narrow-angle glaucoma or a known allergy to any of the product’s components.

How should Mirus be stored and disposed of?

Official Storage and Disposal Requirements

Official labeling mandates specific conditions for storing Mirus (Naphazoline/Pheniramine Ophthalmic Solution) to maintain its integrity and safety.

  • Storage Environment: The product must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The solution must be protected from light and must not be frozen.
  • Container Integrity: The bottle must be kept tightly closed after each use, and the container tip should not touch any surface to prevent contamination. Do not use the product if the solution changes color or becomes cloudy.
  • Child Safety: It is strictly required to keep Mirus out of the sight and reach of children due to the serious risk of accidental ingestion.
  • Disposal: Unused or expired medication must be discarded according to local regulations and official pharmaceutical waste guidelines. Do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirus found in:

A-Z Index: